Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated neuropathy. It affects ...

75 A meta-analysis evaluated 8 studies that compared IVIg and SCIg in patients with autoimmune neuropathies, including multifocal motor neuropathy (n = 50) and CIDP (n = 88). 77 Results found no ...

Chronic inflammatory demyelinating polyneuropathy (CIDP), also known as chronic inflammatory demyelinating polyradiculoneuropathy, occurs when immune-mediated inflammation and autoantibodies cause ...

Background: Chronic inflammatory demyelinating polyradiculoneuropathy is a rare acquired immune-mediated progressive or relapsing disorder causing peripheral neuropathic disease of duration more ...

Dianthus Therapeutics is advancing treatments for autoimmune diseases. Read why DNTH stock is receiving Buy ratings and price ...

(RTTNews) - argenx SE (ARGX) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy. VYVDURA is ...

Vyvgart Hytrulo is a prescription medicine used for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). The ADHERE trial was a multicenter, randomized, ...

Chronic inflammatory demyelinating polyneuropathy is an immune-mediated neuropathy that affects the peripheral motor and sensory nerves. The symptoms are of a slowly progressive numbness and tingling ...

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an autoimmune disorder characterized by the progressive damage to the peripheral nerves, leading to weakness and sensory loss.

Chronic inflammatory demyelinating polyneuropathy (CIDP) affects the peripheral nerves. Tests to diagnose this condition include nerve conduction studies, electromyography, and sometimes an MRI.